The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bohnsack, J. F.
Right arrow Articles by Hill, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bohnsack, J. F.
Right arrow Articles by Hill, H. R.

The Journal of Immunology, Vol 143, Issue 10 3338-3342, Copyright © 1989 by American Association of Immunologists

ARTICLES

An IgA monoclonal antibody directed against type III antigen on group B streptococci acts as an opsonin

JF Bohnsack, MM Hawley, DG Pritchard, ML Egan, AO Shigeoka, KD Yang and HR Hill
Department of Pediatrics, University of Utah School of Medicine, Salt Lake City 84132.

We have investigated the mechanisms by which a murine IgA mAb directed against the type III Ag (IgA anti-III mAb) of group B streptococci (GBS) protects neonatal rats from lethal infection with these organisms. Purified IgA anti-III mAb enhanced phagocytosis of type III GBS by rat peritoneal macrophages in vitro by fourfold compared with phagocytosis of buffer-treated GBS. In the absence of antibody, neonatal rat serum did not promote phagocytosis, but addition of neonatal rat serum to GBS opsonized with IgA anti-III led to a sevenfold increase in phagocytosis. Heat inactivation of C destroyed the ability of neonatal rat serum to enhance phagocytosis in the presence of IgA. C3 deposition was observed when GBS coated with IgA anti-III mAb were incubated in untreated neonatal rat serum or in serum treated with Mg/EGTA. This latter observation suggested that C3 deposition occurred through activation of the alternative pathway. The control IgA mAb MOPC 315 did not enhance GBS ingestion or C3 deposition on GBS. Depletion of C in vivo by using cobra venom factor abolished the protective effect of IgA anti-III mAb in the neonatal rat model. These data suggest that the ability of this IgA to activate C further enhances its opsonic activity and may be essential for its protective effect in vivo.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Sandin, S. Linse, T. Areschoug, J. M. Woof, J. Reinholdt, and G. Lindahl
Isolation and Detection of Human IgA Using a Streptococcal IgA-Binding Peptide
J. Immunol., August 1, 2002; 169(3): 1357 - 1364.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
E. R. Brandt, W. A. Hayman, B. Currie, J. Carapetis, D. C. Jackson, K.-A. Do, and M. F. Good
Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities
Int. Immunol., April 1, 1999; 11(4): 569 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Microbiol. Mol. Biol. Rev.Home page
H. Marcotte and M. C. Lavoie
Oral Microbial Ecology and the Role of Salivary Immunoglobulin A
Microbiol. Mol. Biol. Rev., March 1, 1998; 62(1): 71 - 109.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1989 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1989 by The American Association of Immunologists, Inc. All rights reserved.